Hemoglobin A1c (HbA1c) Testing Market Report 2024

This Hemoglobin A1c (HbA1c) Testing market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The hemoglobin A1c (HbA1c) testing market size has grown rapidly in recent years. It will grow from $1.66 billion in 2023 to $1.83 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth during the historic period can be attributed to several factors, the rising prevalence of diabetes, increased awareness and screening programs, expanding government initiatives and healthcare policies, development of healthcare infrastructure, a growing aging population, improved diagnostic accuracy, and greater adoption of point-of-care testing.

The hemoglobin A1c (HbA1c) testing market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The anticipated growth during the forecast period can be attributed to several factors, the rising prevalence of lifestyle diseases, increased emphasis on preventive healthcare, expansion into emerging markets, growing focus on personalized medicine and patient-centric care, supportive regulatory and reimbursement policies, and advancements in telemedicine and remote monitoring. Key trends expected to drive this growth include technological advancements, integration with digital health platforms, progress in non-invasive testing technologies, expansion in telehealth services, and enhancements in remote patient monitoring.

The growing prevalence of diabetes is expected to drive the expansion of the hemoglobin A1c (HbA1c) testing market. Diabetes is a chronic condition where the body struggles to regulate blood glucose levels due to inadequate insulin production or insulin resistance. The rise in diabetes cases is attributed to factors such as poor diet - particularly high consumption of processed foods and sugary drinks - and sedentary lifestyles with minimal physical activity. Additionally, the aging population and genetic predisposition increase the likelihood of developing diabetes. HbA1c testing is essential for monitoring long-term blood glucose control by measuring average blood sugar levels over the past 2-3 months. For example, data from The Lancet in June 2023 projected that global diabetes cases would grow from 529 million in 2021 to 1.3 billion by 2050. Consequently, the increasing prevalence of diabetes will fuel the growth of the HbA1c testing market.

Leading companies in the HbA1c testing market are concentrating on developing automated analyzers, such as those using high-performance liquid chromatography (HPLC) technology, to improve accuracy and efficiency in diabetes diagnosis and monitoring. HPLC-based solutions are advanced methods for precisely measuring hemoglobin variants in blood, which helps in monitoring long-term glucose control in diabetic patients. For instance, in June 2021, Trivitron Healthcare Private Limited, an India-based medical technology company, introduced the NANO H5 and NANO H110. The NANO H5 is a compact, automated HPLC analyzer that quantifies glycated hemoglobin (HbA1c) in whole blood with a processing time of 130 seconds, allowing for rapid laboratory results and the capability to process up to five samples simultaneously. The NANO H110 is another compact, automated HPLC analyzer with dual test modes for both HbA1c and Hb Variant detection. It features advanced components such as a barcode scanner and cap piercing, with a high sample capacity of 110, making it suitable for medium to large laboratories.

In January 2024, Roche Holding AG, a Swiss pharmaceutical and diagnostics company, acquired point-of-care (POC) technology from LumiraDx for $350 million. This acquisition aims to expand Roche's diagnostics portfolio and enhance its capabilities in decentralized healthcare settings, providing quick and reliable tests, including the CE-marked HbA1c test, without requiring specialized storage. LumiraDx is a UK-based company specializing in point-of-care (POC) technology and offering immunoassay and clinical chemistry tests for HbA1c.

Major companies operating in the hemoglobin A1c (HbA1c) testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Tosoh Corporation, Hitachi High-Technologies Corporation, Beckman Coulter Inc, Sysmex Corporation, Bio Rad Laboratories Inc, ARKRAY Inc, Randox Laboratories Ltd, Ortho Clinical Diagnostics, Agappe Diagnostics Ltd, SEKISUI Diagnostics LLC, Helena Laboratories, Transasia Bio Medicals Ltd, EKF Diagnostics, Trinity Biotech plc, HemoCue AB, CPC Diagnostics Pvt Ltd, PTS Diagnostics, Menarini Diagnostics srl, Diazyme Laboratories Inc, Osang HealthCare Co Ltd, Eurolyser Diagnostica GmbH, DiaSys Diagnostic Systems GmbH.

North America was the largest region in the hemoglobin A1c (HbA1c) testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemoglobin A1c (HbA1c) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hemoglobin A1c (HbA1c) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hemoglobin A1c (HbA1c) testing measures the percentage of hemoglobin with glucose attached, providing an indication of average blood glucose levels over the past 2 to 3 months. It is used to monitor long-term glucose control in diabetic patients and to diagnose diabetes and prediabetes.

The main types of HbA1c testing are laboratory-based testing and point-of-care (PoC) testing. Laboratory-based testing is conducted in a lab setting where blood samples are analyzed using advanced equipment. Product types for this testing include instruments, reagents, kits, and technologies. These technologies encompass immunoassays, chromatography, enzymatic assays, boronate affinity chromatography, high-performance liquid chromatography, and others. End users of HbA1c testing include hospitals and clinics, diagnostic laboratories, homecare settings, and other medical environments.

The hemoglobin A1c (HbA1c) testing market research report is one of a series of new reports that provides hemoglobin A1c (HbA1c) testing market statistics, including hemoglobin A1c (HbA1c) testing industry global market size, regional shares, competitors with an hemoglobin A1c (HbA1c) testing market share, detailed hemoglobin A1c (HbA1c) testing market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobin A1c (HbA1c) testing industry. This hemoglobin A1c (HbA1c) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemoglobin A1c (HbA1c) testing market consists of revenues earned by entities by providing services such as home monitoring services, remote patient monitoring solutions, specialized HbA1c assay development, telehealth HbA1c monitoring, and personalized treatment management consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemoglobin A1c (HbA1c) testing market also includes sales of diagnostic reagents, test cartridges, automated analyzers, and calibration standards. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.